Vaginal Antifungals Market Sets Sights on a Noteworthy US$1.76 Billion Valuation by 2033

Vaginal Antifungals Market

The vaginal antifungals market sales is expected to develop at a 4.5% compound annual growth rate (CAGR) throughout the forecast period, reaching a worth of US$ 1.09 billion in 2022. According to a recent report by Future Market Insights, Polygenes is expected to hold the top rank with a about 49.0% share in the global market in 2022.

During the projection period, it is anticipated that the global market for Vaginal Antifungals will expand significantly. This can be attributed to the expansion of novel antifungal drug research and the global increase in healthcare spending. Additionally, the market is being driven by the increased incidence of bacterial vaginosis. In women of reproductive age, it is the most frequent source of vaginal discharge that results in fungus infections.

Rising trichomoniasis and candida occurrences are also assisting market growth for Vaginal Antifungals. The primary causes of candida growth that leads to vaginal yeast infection include a weakened immune system and the use of oral contraceptives or hormone therapy that increases estrogen levels.

Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-17096

In addition, businesses are concentrating on winning clearance for innovative items that could fill unmet demands and strengthen their market position. Additionally, the growing need for better therapeutic options is spurring advancements in R&D, fresh approvals, and drug launches, opening up a lucrative window for business expansion.

Key Takeaways:

• Polyenes are the leading segment as product, and hold around 49.0% market value share in 2022, owing to less adverse effects and low product cost.
• Topical segment is set to lead in the of route of administration segment of Vaginal Antifungals market with a projected market value share of around 73.1% in 2022, owing to the high preference by doctors and effective cure for the disease.
• Bacterial Vaginosis is leading the indication segment with the significant market share of 44.9% owed to increased prevalence compared to other indications.
• By distribution channel, Gynaecology clinics held a share of around 41.4% in 2022, as patient pool largely comprises of female population who prefer to get consultation and treatment at Gynecology centers.
• North America dominated the global market with significant contribution from U.S. region. US held a value share of around 27.0% in 2022 globally, due to rising prevalence of trichomoniasis in the region.

“Rising prevalence of severe vaginal infectious disorders, increasing rate of testing and launch of Vaginal Antifungals by players will boost the global market for Vaginal Antifungals,” says an analyst at Future Market Insights.

Market Competition:

The market participants are concentrating on creating and introducing enhanced treatment drugs in order to increase the accuracy and efficiency of the operations and reduce adverse effect problems.

• Brexafemme, a high-class antifungal for the treatment of vulvovaginal candidiasis (VCC), will be commercialised and further developed by GSK plc and SCYNEXIS Inc. in 2023 under an exclusive licencing agreement. These drugs have also been approved by the FDA.

Request Report Methodology:https://www.futuremarketinsights.com/request-report-methodology/rep-gb-17096

Key Players:

• Pfizer Inc.
• Bausch Health Companies Inc
• ANI Pharmaceuticals, Inc.
• Hikma Pharmaceuticals Plc
• Lupin Limited
• Mycovia Pharmaceuticals, Inc.
• Glenmark Pharmaceuticals Limited
• GSK plc.
• Others

Key Market Segments Covered:

By Product:

• Polyenes
• Azoles
• Allylamines
• Echinocandins
• Others

By Route of Administration:

• Oral
• Topical

By Indication:

• Bacterial Vaginosis
• Candidiasis
• Trichomoniasis
• Others

Distribution Channel:

• Hospital Pharmacies
• Supermarkets/hypermarkets
• Online Pharmacies
• Gynecology Clinics
• Others

Unlock Tailored Insights: Customize Your Report for Maximum Impact :
https://www.futuremarketinsights.com/customization-available/rep-gb-17096

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube